Results 131 to 140 of about 16,194 (165)

IL28B in the Era of Direct-acting Antivirals for Hepatitis C

Journal of Clinical Gastroenterology, 2013
The IL28B genotype is the strongest baseline predictor of hepatitis C treatment response with peginterferon-α and ribavirin. In 2011, 2 protease inhibitors were approved for genotype 1 infection in combination with peginterferon-α and ribavirin, and boceprevir and telaprevir attenuate the association between the IL28B genotype and treatment response ...
openaire   +2 more sources

Direct-acting antivirals for paediatric HCV: we got there

Nature Reviews Gastroenterology & Hepatology, 2017
In a new report, adolescents with genotype 2 or 3 HCV infection who were given sofosbuvir and ribavirin showed a near 100% sustained virologic response. This study is the beginning of a new wave of treatments for paediatric HCV infection, forming part of a global strategy to eradicate viral hepatitis.
openaire   +2 more sources

Direct acting antiviral therapy after liver transplantation

Current Opinion in Gastroenterology, 2016
Historically, postliver transplant patients with chronic hepatitis C have had worse outcomes than nonhepatitis C-related causes because of accelerated fibrosis posttransplantation and the lack of effective well tolerated therapies for hepatitis C, and posttransplant hepatitis C patients have been considered a special population.
openaire   +2 more sources

Direct-acting antiviral treatment for HCV

The Lancet Infectious Diseases, 2016
Stelliana, Goutzamanis, Joseph, Doyle, Alexander, Thompson, Margaret, Hellard, Peter, Higgs   +4 more
openaire   +2 more sources

Direct-Acting Antiviral Agents

Clinics in Liver Disease, 2015
Tatyana Kushner, Vandana Khungar
openaire   +1 more source

Direct-acting antiviral agents for the treatment of HCV

Antiviral Therapy, 2012
Alexander J, Thompson, Stephen, Locarnini   +1 more
openaire   +2 more sources

Direct‐acting antivirals and recurrence of hepatocellular carcinoma

Liver Transplantation, 2017
Jorge A, Marrero, Amit G, Singal
openaire   +2 more sources

Clinical benefits of direct‐acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta‐analysis

Journal of Gastroenterology and Hepatology (Australia), 2022
Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong   +2 more
exaly  

Direct-acting antiviral treatment for hepatitis C

The Lancet, 2019
Jacinta A, Holmes, Stephanie M, Rutledge, Raymond T, Chung   +2 more
openaire   +2 more sources

Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals

Therapeutic Advances in Gastroenterology, 2020
Cloe Comarmond, Patrice Cacoub, David Saadoun   +2 more
exaly